Log in

NASDAQ:HOTH - Hoth Therapeutics Stock Price, Forecast & News

$4.52
+0.11 (+2.49 %)
(As of 02/24/2020 01:20 AM ET)
Today's Range
$4.41
Now: $4.52
$4.66
50-Day Range
$4.12
MA: $4.98
$6.42
52-Week Range
$3.26
Now: $4.52
$9.07
Volume5,868 shs
Average Volume85,885 shs
Market Capitalization$45.74 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hoth Therapeutics, Inc., a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company was incorporated in 2017 and is based in New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HOTH
CUSIPN/A
CIKN/A
Phone646-756-2997

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-2,500,000.00

Miscellaneous

Employees2
Market Cap$45.74 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive HOTH News and Ratings via Email

Sign-up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.


Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Hoth Therapeutics.

What price target have analysts set for HOTH?

2 brokers have issued 12-month target prices for Hoth Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 121.2% from the stock's current price. View Analyst Price Targets for Hoth Therapeutics.

What is the consensus analysts' recommendation for Hoth Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hoth Therapeutics.

Has Hoth Therapeutics been receiving favorable news coverage?

News stories about HOTH stock have been trending very positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hoth Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Hoth Therapeutics.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a drop in short interest in January. As of January 31st, there was short interest totalling 19,300 shares, a drop of 49.6% from the January 15th total of 38,300 shares. Based on an average trading volume of 28,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.4% of the shares of the stock are short sold. View Hoth Therapeutics' Current Options Chain.

Who are some of Hoth Therapeutics' key competitors?

What other stocks do shareholders of Hoth Therapeutics own?

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the folowing people:
  • Mr. Robb Knie, Pres, CEO & Director (Age 50)
  • Mr. David S. Briones, Chief Financial Officer (Age 43)
  • Ms. Jane H. Behrmann, VP of Operations (Age 34)

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $4.52.

How big of a company is Hoth Therapeutics?

Hoth Therapeutics has a market capitalization of $45.74 million. The company earns $-2,500,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Hoth Therapeutics employs 2 workers across the globe.View Additional Information About Hoth Therapeutics.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is http://www.hoththerapeutics.com/.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]


MarketBeat Community Rating for Hoth Therapeutics (NASDAQ HOTH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  53 (Thanks for Voting!)
Underperform Votes:  61 (Thanks for Voting!)
Total Votes:  114
MarketBeat's community ratings are surveys of what our community members think about Hoth Therapeutics and other stocks. Vote "Outperform" if you believe HOTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel